MannKind Corp (MNKD)

• Market cap: $1.13B
• 1 day: -3.13%
• 5 days: -16.44%
• 1 month: -21.40%
• 3 months: -27.96%
• 6 months: -43.27%
• Year to date: -43.79%
• 1 year: -26.39%
• 5 years: 123.49%
• 10 years: -87.84%
• Sector: Healthcare
• Industry: Biotechnology

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Employees: 407

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

472% more call options, than puts

Call options by funds: $9M | Put options by funds: $1.57M

58% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 26

13% more repeat investments, than reductions

Existing positions increased: 80 | Existing positions reduced: 71

5% more funds holding

Funds holding: 240 [Q4 2024] → 252 (+12) [Q1 2025]

2.8% less ownership

Funds ownership: 60.84% [Q4 2024] → 58.04% (-2.8%) [Q1 2025]

18% less capital invested

Capital invested by funds: $1.08B [Q4 2024] → $886M (-$193M) [Q1 2025]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 223% upside
• Avg. target: $12 223% upside
• High target: $12 223% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Mizuho

223% upside $12

Outperform Initiated

10 Apr 2025